NASDAQ:RPTX Repare Therapeutics (RPTX) Stock Price, News & Analysis $2.82 +0.07 (+2.55%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.73▼$2.8950-Day Range$2.75▼$3.9952-Week Range$2.71▼$13.85Volume65,617 shsAverage Volume175,393 shsMarket Capitalization$119.69 millionP/E RatioN/ADividend YieldN/APrice Target$17.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Repare Therapeutics alerts: Email Address Repare Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside514.7% Upside$17.33 Price TargetShort InterestHealthy2.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.11Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.31) to ($3.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.06 out of 5 starsMedical Sector321st out of 910 stocksPharmaceutical Preparations Industry137th out of 426 stocks 3.6 Analyst's Opinion Consensus RatingRepare Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRepare Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Repare Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.58% of the float of Repare Therapeutics has been sold short.Short Interest Ratio / Days to CoverRepare Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Repare Therapeutics has recently decreased by 0.78%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRepare Therapeutics does not currently pay a dividend.Dividend GrowthRepare Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RPTX. Previous Next 2.8 News and Social Media Coverage News SentimentRepare Therapeutics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Repare Therapeutics this week, compared to 2 articles on an average week.Search Interest5 people have searched for RPTX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Repare Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repare Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.60% of the stock of Repare Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.09% of the stock of Repare Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Repare Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Repare Therapeutics are expected to decrease in the coming year, from ($2.31) to ($3.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repare Therapeutics is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Repare Therapeutics is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRepare Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Repare Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Repare Therapeutics Stock (NASDAQ:RPTX)Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.Read More RPTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPTX Stock News HeadlinesSeptember 6 at 4:21 AM | americanbankingnews.comRepare Therapeutics (NASDAQ:RPTX) Stock Rating Reaffirmed by HC WainwrightSeptember 6 at 12:26 AM | markets.businessinsider.comBuy Rating on Repare Therapeutics: Strategic Reprioritization and Upcoming Catalysts Bolster Long-Term ProspectsSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 3, 2024 | markets.businessinsider.comBuy Rating on Repare Therapeutics Amidst Promising Clinical Trials and Strong FinancialsAugust 31, 2024 | bizjournals.comMontreal-Cambridge biotech to lay off 25% of teamAugust 31, 2024 | seekingalpha.comRepare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib DataAugust 29, 2024 | msn.comRepare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada's Evolving Economic LandscapeAugust 29, 2024 | finance.yahoo.comRepare Therapeutics: A Promising Penny Stock in Canada’s Evolving Economic LandscapeSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 29, 2024 | msn.comRepare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada’s Evolving Economic LandscapeAugust 29, 2024 | markets.businessinsider.comStrategic Restructuring and Promising Pipeline Underpin Buy Rating for Repare TherapeuticsAugust 28, 2024 | businesswire.comRepare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical PortfolioAugust 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Repare Therapeutics Amid Promising Clinical Data and Strategic Financial PositioningAugust 20, 2024 | markets.businessinsider.comMorgan Stanley Sticks to Its Hold Rating for Repare Therapeutics (RPTX)August 17, 2024 | finance.yahoo.comRPTX Sep 2024 5.000 put (RPTX240920P00005000)August 9, 2024 | markets.businessinsider.comRepare Therapeutics: Strong Q2 Financials and Upcoming Catalysts Bolster Buy RatingAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Repare Therapeutics Amid Anticipated Catalysts and Strong FinancialsAugust 7, 2024 | markets.businessinsider.comOptimistic Buy Rating for Repare Therapeutics on Strong Financials and Clinical SuccessSee More Headlines Receive RPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RPTX CUSIPN/A CIK1808158 Webwww.reparerx.com Phone857-412-7018FaxN/AEmployees180Year Founded2016Price Target and Rating Average Stock Price Target$17.33 High Stock Price Target$25.00 Low Stock Price Target$10.00 Potential Upside/Downside+514.7%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,800,000.00 Net Margins-99.76% Pretax Margin-121.83% Return on Equity-31.11% Return on Assets-26.39% Debt Debt-to-Equity RatioN/A Current Ratio7.27 Quick Ratio7.27 Sales & Book Value Annual Sales$68.68 million Price / Sales1.74 Cash FlowN/A Price / Cash FlowN/A Book Value$5.03 per share Price / Book0.56Miscellaneous Outstanding Shares42,445,000Free Float33,277,000Market Cap$119.69 million OptionableOptionable Beta0.71 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Lloyd Mitchell Segal (Age 60)President, CEO & Director Comp: $932.18kMr. Steve Forte (Age 45)Executive VP & CFO Comp: $632kDr. Maria Koehler M.D. (Age 67)Ph.D., Executive VP & Chief Medical Officer Comp: $693.28kDr. Daniel Durocher Ph.D.Co-FounderDr. Frank Sicheri Ph.D.Co-FounderDr. Agnel Sfeir Ph.D.Co-FounderDr. Michael Zinda Ph.D. (Age 53)Executive VP & Chief Scientific Officer Comp: $641.53kMr. Daniel BelangerExecutive Vice President of Human ResourceMr. Cameron BlackExecutive Vice President of DiscoveryDr. Kim A. Seth Ph.D.Executive VP & Chief Business OfficerMore ExecutivesKey CompetitorsBlack Diamond TherapeuticsNASDAQ:BDTXAlectorNASDAQ:ALECVerve TherapeuticsNASDAQ:VERVSage TherapeuticsNASDAQ:SAGECOMPASS PathwaysNASDAQ:CMPSView All CompetitorsInsiders & InstitutionsBlue Owl Capital Holdings LPBought 250,000 shares on 8/15/2024Ownership: 7.945%Squarepoint Ops LLCBought 115,916 shares on 8/14/2024Ownership: 0.337%Bank of Montreal CanBought 5,673 shares on 8/14/2024Ownership: 0.261%Marshall Wace LLPBought 82,590 shares on 8/14/2024Ownership: 0.195%XTX Topco LtdBought 33,320 shares on 8/12/2024Ownership: 0.079%View All Insider TransactionsView All Institutional Transactions RPTX Stock Analysis - Frequently Asked Questions How have RPTX shares performed this year? Repare Therapeutics' stock was trading at $7.30 on January 1st, 2024. Since then, RPTX shares have decreased by 61.4% and is now trading at $2.82. View the best growth stocks for 2024 here. How were Repare Therapeutics' earnings last quarter? Repare Therapeutics Inc. (NASDAQ:RPTX) released its earnings results on Tuesday, August, 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.03. The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $4.02 million. Repare Therapeutics had a negative trailing twelve-month return on equity of 31.11% and a negative net margin of 99.76%. When did Repare Therapeutics IPO? Repare Therapeutics (RPTX) raised $126 million in an initial public offering on Friday, June 19th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO. Who are Repare Therapeutics' major shareholders? Repare Therapeutics' top institutional shareholders include Blue Owl Capital Holdings LP (7.94%), ARK Investment Management LLC (6.20%), Renaissance Technologies LLC (1.08%) and Acadian Asset Management LLC (0.98%). Insiders that own company stock include Bvf Partners L P/Il, Lloyd Mitchell Segal, Michael Zinda, Steve Forte, Thomas Civik and David P Bonita. View institutional ownership trends. How do I buy shares of Repare Therapeutics? Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Repare Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT) and This page (NASDAQ:RPTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.